The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective?
作者： Kelly Lien , Scott Berry , Yoo-Joung Ko , Kelvin KW Chan
DOI: 10.1586/14737167.2015.982100
关键词:
摘要: Cetuximab (Erbitux) and panitumumab (Vectibix) are monoclonal antibodies to the EGFR. They used as monotherapy or in combination with cytotoxic chemotherapy increase both progression-free survival overall patients wild-type RAS metastatic colorectal cancer. The most common side effects of therapy dermatological, including skin (acneiform) rash, pruritus hair changes. Despite their clinical activity, cost–effectiveness two drugs should be addressed a discussion usage everyday care. This study provides an up-to-date review efficacy anti-EGFR inhibitors.
informahealthcare.com参考文章(91)
Cong Tan, Xiang Du, KRAS mutation testing in metastatic colorectal cancer World Journal of Gastroenterology. ,vol. 18, pp. 5171- 5180 ,(2012) , 10.3748/WJG.V18.I37.5171
Martin Frank, Thomas Mittendorf, Influence of Pharmacogenomic Profiling Prior to Pharmaceutical Treatment in Metastatic Colorectal Cancer on Cost Effectiveness PharmacoEconomics. ,vol. 31, pp. 215- 228 ,(2013) , 10.1007/S40273-012-0017-2
Lulu Huang, Zhenfang Liu, Donghong Deng, Aihua Tan, Ming Liao, Zengnan Mo, Xiaobo Yang, Systematic review/Meta-analysis Anti-epidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients Archives of Medical Science. ,vol. 1, pp. 1- 9 ,(2014) , 10.5114/AOMS.2014.40728
Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling-Kaiser, Salah-Eddin Al-Batran, Tobias Heintges, Juergen Lerchenmueller, Christoph Kahl, Gernot Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, Joerg Hielscher, Michael Scholz, Sebastian Mueller, Britta Schaefer, Dominik Paul Modest, Andreas Jung, Sebastian Stintzing, Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). Journal of Clinical Oncology. ,vol. 31, ,(2013) , 10.1200/JCO.2013.31.15_SUPPL.LBA3506
Michelle Joy Naughton, Deborah Schrag, Alan Paul Venook, Donna Niedzwiecki, Roger T. Anderson, Heinz-Josef Lenz, Stephen S. Grubbs, Quality of life (QOL) and toxicity among patients in CALGB 80405. Journal of Clinical Oncology. ,vol. 31, pp. 3611- 3611 ,(2013) , 10.1200/JCO.2013.31.15_SUPPL.3611
J. Metges, J. Raoul, N. Achour, O. Capitain, A. Gourlaouen, J. Ramée, J. Egreteau, J. Douillard, S. Traoré, F. Grudé, PANERB study: Panitumumab after cetuximab-based regimen failure. Journal of Clinical Oncology. ,vol. 28, ,(2010) , 10.1200/JCO.2010.28.15_SUPPL.E14000
A de Gramont, J F Bosset, C Milan, P Rougier, O Bouché, P L Etienne, F Morvan, C Louvet, T Guillot, E François, L Bedenne, Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. Journal of Clinical Oncology. ,vol. 15, pp. 808- 815 ,(1997) , 10.1200/JCO.1997.15.2.808
Christina Wu, Aline Charabaty, Michael Pishvaian, John L. Marshall, Molecularly targeted therapy for metastatic colon cancer: proven treatments and promising new agents. Current Colorectal Cancer Reports. ,vol. 4, pp. 15- 21 ,(2010) , 10.1007/S11888-010-0061-2
Leonard Saltz, Suprith Badarinath, Shaker Dakhil, Bryan Bienvenu, W. Graydon Harker, George Birchfield, Laurence K. Tokaz, David Barrera, Paul R. Conkling, Mark A. O'Rourke, Donald A. Richards, Diane Reidy, David Solit, Efsevia Vakiani, Marinella Capanu, Amy Scales, Feng Zhan, Kristi A. Boehm, Lina Asmar, Allen Cohn, Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. Clinical Colorectal Cancer. ,vol. 11, pp. 101- 111 ,(2012) , 10.1016/J.CLCC.2011.05.006